Journal Article
H. M. Moulton, Yoshihara, P. H., Mason, D. H., Iversen, P. L., and Triozzi, P. L.,
“Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.”,
Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 8, no. 7, pp. 2044-51, 2002.
B. W. Neuman, Stein, D. A., Kroeker, A. D., Paulino, A. D., Moulton, H. M., Iversen, P. L., and Buchmeier, M. J.,
“Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.”,
Journal of virology, vol. 78, no. 11, pp. 5891-9, 2004.
G. McClorey, Moulton, H. M., Iversen, P. L., Fletcher, S., and Wilton, S. D.,
“Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.”,
Gene therapy, vol. 13, no. 19, pp. 1373-81, 2006.
R. Burrer, Neuman, B. W., Ting, J. P. C., Stein, D. A., Moulton, H. M., Iversen, P. L., Kuhn, P., and Buchmeier, M. J.,
“Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models.”,
Journal of virology, vol. 81, no. 11, pp. 5637-48, 2007.
R. Abes, Arzumanov, A., Moulton, H. M., Abes, S., Ivanova, G., Gait, M. J., Iversen, P., and Lebleu, B.,
“Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides.”,
Journal of peptide science : an official publication of the European Peptide Society, vol. 14, no. 4, pp. 455-60, 2008.
N. B. Marshall, Oda, S. K., London, C. A., Moulton, H. M., Iversen, P. L., Kerkvliet, N. I., and Mourich, D. V.,
“Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.”,
Journal of immunological methods, vol. 325, no. 1-2, pp. 114-26, 2007.
M. H. Nelson, Stein, D. A., Kroeker, A. D., Hatlevig, S. A., Iversen, P. L., and Moulton, H. M.,
“Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.”,
Bioconjugate chemistry, vol. 16, no. 4, pp. 959-66, 2005.
B. Lebleu, Moulton, H. M., Abes, R., Ivanova, G. D., Abes, S., Stein, D. A., Iversen, P. L., Arzumanov, A. A., and Gait, M. J.,
“Cell penetrating peptide conjugates of steric block oligonucleotides.”,
Advanced drug delivery reviews, vol. 60, no. 4-5, pp. 517-29, 2008.
H. Yin, Moulton, H. M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P., and Wood, M. J. A.,
“Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.”,
Human molecular genetics, vol. 17, no. 24, pp. 3909-18, 2008.
H. M. Moulton, Fletcher, S., Neuman, B. W., McClorey, G., Stein, D. A., Abes, S., Wilton, S. D., Buchmeier, M. J., Lebleu, B., and Iversen, P. L.,
“Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.”,
Biochemical Society transactions, vol. 35, no. Pt 4, pp. 826-8, 2007.
R. P. Wu, Youngblood, D. S., Hassinger, J. N., Lovejoy, C. E., Nelson, M. H., Iversen, P. L., and Moulton, H. M.,
“Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity.”,
Nucleic acids research, vol. 35, no. 15, pp. 5182-91, 2007.
R. Abes, Arzumanov, A. A., Moulton, H. M., Abes, S., Ivanova, G. D., Iversen, P. L., Gait, M. J., and Lebleu, B.,
“Cell-penetrating-peptide-based delivery of oligonucleotides: an overview.”,
Biochemical Society transactions, vol. 35, no. Pt 4, pp. 775-9, 2007.
H. M. Moulton, Nelson, M. H., Hatlevig, S. A., Reddy, M. T., and Iversen, P. L.,
“Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.”,
Bioconjugate chemistry, vol. 15, no. 2, pp. 290-9, 2004.
D. L. Swenson, Warfield, K. L., Warren, T. K., Lovejoy, C., Hassinger, J. N., Ruthel, G., Blouch, R. E., Moulton, H. M., Weller, D. D., Iversen, P. L., and Bavari, S.,
“Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.”,
Antimicrobial agents and chemotherapy, vol. 53, no. 5, pp. 2089-99, 2009.
F. Debart, Abes, S., Deglane, G., Moulton, H. M., Clair, P., Gait, M. J., Vasseur, J. - J., and Lebleu, B.,
“Chemical modifications to improve the cellular uptake of oligonucleotides.”,
Current topics in medicinal chemistry, vol. 7, no. 7, pp. 727-37, 2007.
H. Yin, Boisguerin, P., Moulton, H. M., Betts, C., Seow, Y., Boutilier, J., Wang, Q., Walsh, A., Lebleu, B., and Wood, M. J. A.,
“Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency.”,
Molecular therapy. Nucleic acids, vol. 2, p. e124, 2013.
H. Yin, Moulton, H. M., Betts, C., and Wood, M.,
“CPP-directed oligonucleotide exon skipping in animal models of Duchenne muscular dystrophy.”,
Methods in molecular biology (Clifton, N.J.), vol. 683, pp. 321-38, 2011.
R. Abes, Moulton, H. M., Clair, P., Yang, S. - T., Abes, S., Melikov, K., Prevot, P., Youngblood, D. S., Iversen, P. L., Chernomordik, L. V., and Lebleu, B.,
“Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies.”,
Nucleic acids research, vol. 36, no. 20, pp. 6343-54, 2008.
B. W. Neuman, Bederka, L. H., Stein, D. A., Ting, J. P. C., Moulton, H. M., and Buchmeier, M. J.,
“Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors.”,
Antimicrobial agents and chemotherapy, vol. 55, no. 10, pp. 4631-8, 2011.
A. Crisp, Yin, H., Goyenvalle, A., Betts, C., Moulton, H. M., Seow, Y., Babbs, A., Merritt, T., Saleh, A. F., Gait, M. J., Stuckey, D. J., Clarke, K., Davies, K. E., and Wood, M. J. A.,
“Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.”,
Human molecular genetics, vol. 20, no. 3, pp. 413-21, 2011.
S. Fletcher, Adams, A. M., Johnsen, R. D., Greer, K., Moulton, H. M., and Wilton, S. D.,
“Dystrophin isoform induction in vivo by antisense-mediated alternative splicing.”,
Molecular therapy : the journal of the American Society of Gene Therapy, vol. 18, no. 6, pp. 1218-23, 2010.
M. Nizzardo, Simone, C., Salani, S., Ruepp, M. - D., Rizzo, F., Ruggieri, M., Zanetta, C., Brajkovic, S., Moulton, H. M., Müehlemann, O., Bresolin, N., Comi, G. P., and Corti, S.,
“Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.”,
Clinical therapeutics, vol. 36, no. 3, pp. 340-56.e5, 2014.
X. Gao, Zhao, J., Han, G., Zhang, Y., Dong, X., Cao, L., Wang, Q., Moulton, H. M., and Yin, H.,
“Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice.”,
Molecular therapy : the journal of the American Society of Gene Therapy, vol. 22, no. 7, pp. 1333-41, 2014.